Estrogen receptor (ER) and epidermal growth factor receptor (EGFR) as targets for dual lung cancer therapy: not just a case?
Monica
M
Giovannini
Carmen
C
Belli
Eugenio
E
Villa
Vanesa
V
Gregorc
D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005260:Female; D005500:Follow-Up Studies; D000077156:Gefitinib; D006801:Humans; D000077289:Letrozole; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009570:Nitriles / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use*; D011960:Receptors, Estrogen / Q000037:antagonists & inhibitors*; D012878:Skin Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary; D014230:Triazoles / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D009570:Nitriles; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D011960:Receptors, Estrogen; D014230:Triazoles; D000077289:Letrozole; D066246:ErbB Receptors; D000077156:Gefitinib